BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36825430)

  • 1. Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing.
    Ahmed E; El-Dien A N; Sabet S; Khalifa M; El Hamshary M
    Biomarkers; 2023 Jun; 28(4):379-386. PubMed ID: 36825430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
    Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
    Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
    Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
    Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
    Dhayat SA; Yang Z
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma.
    Ding Y; Yao J; Wen M; Liu X; Huang J; Zhang M; Zhang Y; Lv Y; Xie Z; Zuo J
    PeerJ; 2022; 10():e13473. PubMed ID: 35602894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.
    Ikeda S; Tsigelny IF; Skjevik ÅA; Kono Y; Mendler M; Kuo A; Sicklick JK; Heestand G; Banks KC; Talasaz A; Lanman RB; Lippman S; Kurzrock R
    Oncologist; 2018 May; 23(5):586-593. PubMed ID: 29487225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
    Moldogazieva NT; Zavadskiy SP; Terentiev AA
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.
    Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
    Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
    Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
    Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
    Lyu X; Tsui YM; Ho DW; Ng IO
    Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.